



AED



OxySure Therapeutics (OXYS) Establishes Supply Agreement with ORS Nasco, a Division of Essendant

Frisco, Texas, February 4, 2016 – OxySure Therapeutics, Inc. (OTCQB: OXYS) (“OxySure,” or the “Company”), a global leader and medical device innovator of life-saving, easy-to-use emergency oxygen products with its “oxygen from powder” technology and other innovative emergency medical solutions today announced that the Company has established a supply agreement with ORS Nasco, a division of Essendant, a global distributor of workplace essentials with \$5.4 billion in sales.

“This agreement allows us to offer additional, complimentary offerings to our institutional customers seeking a single source solution for their medical emergency preparedness, therapeutics and medical risk management needs,” stated Julian T. Ross, CEO of OxySure. “In addition to our OxySure Model 615 and related therapeutics and medical emergency offerings, our sales teams can now offer expanded solutions for first aid safety, respiratory protection, heat stress protection and eye protection, to name just a few options.”

OxySure plans to develop a new, enhanced catalog of products which will be expanded to include first aid kits, antiseptics, CPR masks and eye wash solutions in the first aid safety category; disposable and escape respirators in the respiratory protection category; and hydration and cooling solutions in the heat stress protection category.

“We remain committed to developing and selling innovative, patented products in the medical device and therapeutics areas,” said Clark Hood, VP of Sales for OxySure. “At the same time we also recognize we can grow faster by satisfying our institutional customers’ need for a single source solution with highly differentiated service as they seek to continually enhance workplace safety.”

About OxySure Therapeutics, Inc.

OxySure Therapeutics, Inc. (OXYS) is a medical technology company that focuses on the design, manufacture and distribution of specialty respiratory and medical solutions. The company pioneered a safe and easy to use solution to produce medically pure (USP) oxygen from inert powders. The company owns numerous issued patents and patents pending on this technology which makes the provision of emergency oxygen safer, more accessible and easier to use than traditional oxygen provision systems. OxySure's products improve access to emergency oxygen that affects the survival, recovery and safety of individuals in several areas of need: (1) Public and private places and settings where medical emergencies can occur; (2) Individuals at risk for cardiac, respiratory or general medical distress needing immediate help prior to emergency medical care arrival; and (3) Those requiring immediate protection and escape from exposure situations or oxygen-deficient situations in industrial, mining, military, or other "Immediately Dangerous to Life or Health" (IDLH) environments. *In addition to oxygen products for public/lay responder usage, OxySure also markets emergency medical solutions*

including AEDs (Cardiac Science, Philips, Zoll, Physio Control, Defibtech, and HeartSine), Quickclot Bleeding Control solutions, resuscitation products and pulse oximetry products.
www.OxySure.com

Contact:

Redchip Companies, Inc.

Jon Cunningham: jon@redchip.com

800-733-2447, ext. 107

www.redchip.com/

Forward-Looking Statements

Statements in this earnings release that are not historical facts are considered to be forward-looking statements. Such statements include, but are not limited to, statements regarding management beliefs and expectations, based upon information available at the time the statements are made, regarding future plans, objectives and performance. All forward-looking statements are subject to risks and uncertainties, many of which are beyond management's control and actual results and performance may differ significantly from those contained in forward-looking statements. OxySure Therapeutics, Inc. intends any forward-looking statement to be covered by the Litigation Reform Act of 1995 and is including this statement for purposes of said safe harbor provisions. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this news release. OxySure Therapeutics, Inc. undertakes no obligation to update any forward-looking statements to reflect events or circumstances that occur after the date as of which such statements are made. A discussion of certain risks and uncertainties that could cause actual results to differ materially from those contained in forward-looking statements is included in OxySure Therapeutics, Inc.'s Annual Report on Form 10-K for the year ended December 31, 2014.